Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophag... (ed gastrointestinal and other severe tox...)

HOME >> MEDICINE >> TECHNOLOGY

Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer

Date:6/2/2009

ed gastrointestinal and other severe toxicities.

About OPAXIO(TM)

OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that OPAXIO metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

This
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
2. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
3. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
4. Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells
5. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
6. Zetia Does Not Reduce Carotid Plaque Size When Added to Zocor
7. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
8. Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects
9. Winning the War on Cancer: The Critical Role of Radiation Oncology
10. Breast MRI Scan Could Determine Need for Radiation Therapy
11. High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study

Post Your Comments:

(Date:12/15/2009)... -- Masimo (Nasdaq: MASI ), the inventor ... Perfusion pulse oximetry, today announced that Masimo Chairman ... 2009 Frost & Sullivan CEO of the Year ... According to Frost & Sullivan, the award is ... in understanding customer requirements, developing new technologies, delivering ...

(Date:12/15/2009)... MALVERN, Pa. and WALTHAM, Mass., Dec. 15 /PRNewswire/ ... find that methicillin-resistant Staphylococcus aureus (MRSA) ... infectious disease specialists with regard to their treatment ... activity against MRSA is among the top factors ... skin and skin structure infections. Other key factors ...

(Date:12/15/2009)... -- Bend Research Inc. announced,today that its clients may ... used in technologies developed by the firm to enhance ... Bend Research clients may now reference a ... filings with the FDA, Bend Research officials said. , ... development and know it will assist our,clients in accelerating ...

Breaking Medicine Technology:Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 2 Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 3 Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 4 Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 5 Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award 6 A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 2 A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 3 Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient 2 An atomic level look at an HIV accomplice 61728 1 An atomic level look at an HIV accomplice 61728 2 Bioreactor for bone tissue engineering wins professor venture fair 10813 1 Bioreactor for bone tissue engineering wins professor venture fair 10813 2 Bioreactor for bone tissue engineering wins professor venture fair 10813 3 Drug studied as possible treatment for spinal injuries 10811 1 Drug studied as possible treatment for spinal injuries 10811 2 Drug studied as possible treatment for spinal injuries 10811 3

[0] Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award [0] A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections [0] Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient

... in Repeat-Dosing Study in Subjects with ALS, RICHMOND, ... ) announced today that it has opened a Phase,2 ... subjects,with ALS, a progressive, degenerative motor-neuron disease for which ... drug, SB-509, is an injectable formulation of a plasmid,encoding ...

... Sept. 3 Forest Laboratories, Inc.,(NYSE: ... announced results from,two global Phase III studies ... for the treatment of patients with chronic,obstructive ... I&II,(AClidinium CLinical Trial Assessing Efficacy and Safety ...

Other Medicine Technology:Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2 Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3 Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4 Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5 Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2 Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3 Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4 Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5 Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6

Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)

(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... Therapeutics - Market Forecasts to 2015, ... Analysis ,, http://www.reportlinker.com/p0168099/The-Future-of-Respiratory-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ... The author has released its latest ...

(Date:12/15/2009)... NEW YORK, Dec. 15 ... research report is available in its ... of Autoimmune Diseases Therapeutics - Market ... Pipeline and Deals Analysis ... Summary ,, The author has ...

(Date:12/15/2009)... ALPHARETTA, Ga., Dec. 15 Hosted by ... the 4th annual event recognized 2009,s best eLearning ... all, were spread across 4 categories. The ... developed for the world,s largest hotelier, was selected ... Hours of Custom eLearning" category by the panel ...

(Date:12/15/2009)... Ill. and CHENNAI, India, Dec. 15 /PRNewswire-FirstCall/ ... ), the world leader in generic injectable ... (BSE: 524372, NSE: ORCHIDCHEM), a leading Indian ... beta-lactam antibiotics manufacturers globally, today announced an ... injectable finished-dosage form pharmaceuticals business for approximately ...

(Date:12/15/2009)... is being released by the American Health Information Management ... RHIT, CCS, FAHIMA ,, AHIMA President ... ,, On behalf of the A-H-I-M-A Board of Directors...it ... executive officer, Doctor Alan Dowling... ,, Back last summer ... who we knew could effectively replace Linda ...

[0] Reportlinker Adds The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] The Venza Group Received Top Honors at the American Society of Training & Development (ASTD) eLearning Excellence Awards Ceremony Held on December 10, 2009 [0] Hospira to Acquire Orchid's Generic Injectable Pharmaceuticals Business [0] Dowling Press Availability Tuesday, December 15, 2009 / 10:00 a.m. CST

... EntreMed, Inc.,(Nasdaq: ENMD ) a clinical-stage ... and inflammatory diseases,announced today that James S. Burns, ... overview at the Acumen BioFin Rodman & Renshaw ... New York Palace Hotel in,New York, November 5-7, ...

... BPUR ) announced today that the trading symbol ... to BPUR at the open of the market on,Wednesday, ... OTCBB,will revert to the following ticker symbols: BPREW reverting ... BPURL. Biopure Corporation Biopure Corporation develops, manufactures ...

... FRANCISCO, Calif., Oct. 31 Anesiva,Inc. (Nasdaq: ANSV ... chief executive officer, will present at the following events ... November 6, 2007 3:45 p.m. ET ... Healthcare Conference November 27, 2007 4:30 p.m. ...

... QUEBEC CITY, Oct. 31 /PRNewswire-FirstCall/ - AEterna Zentaris ... focused on,endocrine therapy and oncology, will announce its ... open on Wednesday, November,7, 2007. The Company will ... results on the same day at 10:00 a.m. ...

... NORTHAMPTON, Mass., Oct. 31 Physicians ... posts to Healthcommunities.com,Inc.,s healthchannels forum,( http://www.healthcommunities.com/health/forums.shtml ... physician post was submitted to the ... hosted and maintained by,Healthcommunities.com, Inc. (HC), ...

... ALTH ), a biopharmaceutical company focused on,the development ... cancer, today announced that Paul L. Berns, President and,CEO, ... BioFin Rodman &,Renshaw Conference in New York. The ... on,Tuesday, November 6, 2007. There will be a live ...

Other Medicine News:Health News:EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference 2 Health News:Biopure's Stock Symbol Reverts to BPUR 2 Health News:Anesiva Announces Upcoming Webcasts and Conference Participation 2 Health News:Free Site Offering Patient-Physician Dialog Reaches Milestone 2 Health News:Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference 2

EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference Biopure's Stock Symbol Reverts to BPUR Anesiva Announces Upcoming Webcasts and Conference Participation AEterna Zentaris to Announce Third Quarter 2007 Financial and Operating Results on November 7, 2007 Free Site Offering Patient-Physician Dialog Reaches Milestone Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

Medicine Products:

Allergen, Weed, Kochia/Firebush Allergen, Tree, Willow Tree Allergen, Tree, White Ash Tree Allergen, Tree, White Pine Tree

Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophag...(ed gastrointestinal and other severe tox...),Health